Sodium-glucose cotransporter 2 (SGLT2) inhibitors were initially developed as glucose-lowering agents for type 2 diabetes mellitus (T2DM) by reducing proximal tubular glucose reabsorption and promoting glucosuria. Here, SLC5A2 is linked to diabetes mellitus.